[Anti-steroid hormones for uterine cancer]
| Related Articles |
[Anti-steroid hormones for uterine cancer]
Nippon Rinsho. 2008 Jan;66(1):174-81
Authors: Komiyama S, Nishio E, Yasue A, Hasegawa K, Udagawa Y
Endometrial cancer is an estrogen-dependent tumor with increasing incidence in recent years. It can be classified into two types: the more common type 1 tumors are estrogen-dependent, develop in relatively younger patients, and are associated with a relatively good prognosis; while type 2 tumors are estrogen-independent, develop in relatively older patients and are associated with a poorer prognosis. On the other hand, with the increase in breast cancer patients in recent years and with the resulting similar increase in patients on oral tamoxifen treatment, there has been a problematic rise in the incidence of endometrial cancers induced by tamoxifen use. This has necessitated a need for careful observation of these patients as tamoxifen-related endometrial cancers are often type 2 cancers and thus present with a poorer prognosis. A large number of hormonal treatments have been used in the treatment of endometrial cancer; however, only progestin derivatives have demonstrated any effect towards endometrial cancer to date. In general, progestin therapy is used only for fertility-preserving purposes in younger patients. These patients must fulfill the indications of well-differentiated endometrioid adenocarcinoma of Stage Ia; in these patients, medroxyprogesterone acetate (MPA) 400-600 mg/day is administered and treatment effects are evaluated by endometrial biopsy every 8 weeks.
PMID: 18186261 [PubMed - in process]
[Risks and benefits of hormone replacement therapy]
| Related Articles |
[Risks and benefits of hormone replacement therapy]
Nippon Rinsho. 2008 Jan;66(1):163-7
Authors: Akishita M
In contrast to observational studies, clinical trials examining the efficacy of hormone replacement therapy (HRT) have shown the overall negative or deteriorating effects of HRT in postmenopausal women. Particularly, the results of Women’s Health Initiative (WHI) demonstrated that HRT was preventive of fractures and colon cancer but increased the risk of myocardial infarction, stroke and dementia in addition to breast cancer and venous thromboembolism. Conversely, recent progress in androgen research suggests the efficacy of androgen replacement therapy in elderly men, pending clinical trials.
PMID: 18186260 [PubMed - in process]
[(2-Phenylindol-3-yl)methylene]propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G(2)/M phase and apoptosis.
 |
Related Articles |
[(2-Phenylindol-3-yl)methylene]propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G(2)/M phase and apoptosis.
Bioorg Med Chem. 2007 Dec 1;15(23):7368-79
Authors: Pojarová M, Kaufmann D, Gastpar R, Nishino T, Reszka P, Bednarski PJ, von Angerer E
Cell cycle arrest of malignant cells is an important option for cancer treatment. In this study, we modified the structure of antimitotic 2-phenylindole-3-carbaldehydes by condensation with malononitrile. The resulting methylene propanedinitriles inhibited the growth of MDA-MB 231 and MCF-7 breast cancer cells with IC(50) values below 100 nM. Though they exhibited similar structure-activity relationships as the aldehydes, they did not inhibit tubulin polymerization but were capable of blocking the cell cycle in G(2)/M phase. The cell cycle arrest was accompanied by apoptosis as demonstrated by the activation of caspases 3 and 9. Since the new 2-phenylindole derivatives also inhibited the growth of transplanted MXT mouse mammary tumors, they are interesting candidates for further development.
PMID: 17889547 [PubMed - indexed for MEDLINE]
Construction of polyamine-modified uridine and adenosine derivatives–evaluation of DNA binding capacity and cytotoxicity in vitro.
|
Related Articles |
Construction of polyamine-modified uridine and adenosine derivatives–evaluation of DNA binding capacity and cytotoxicity in vitro.
Bioorg Med Chem. 2007 Dec 1;15(23):7426-33
Authors: Ghatnekar J, Hägerlöf M, Oredsson S, Alm K, Elmroth SK, Persson T
We here report the synthesis of the two polyamine-based nucleoside derivatives 5-{[bis-(3-aminopropyl)amino]acetamido-1-propynyl}uridine and 2-{[bis-(3-aminopropyl)amino]-acetamido-1-propynyl}adenosine. The various polyamine derivatives have been used in thermal melting analysis using DNA from herring testes, and in cellular studies using four different cell lines. The compounds were all found to be non-toxic, thus holding good promise for future use as siRNA building blocks.
PMID: 17869123 [PubMed - indexed for MEDLINE]
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a “never-smoked” female patient with advanced non-small cell lung cancer.
|
Related Articles |
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a “never-smoked” female patient with advanced non-small cell lung cancer.
Lung Cancer. 2007 Nov;58(2):296-9
Authors: Usuda J, Ohira T, Suga Y, Oikawa T, Ichinose S, Inoue T, Ohtani K, Maehara S, Imai K, Kubota M, Tsunoda Y, Tsutsui H, Furukawa K, Okunaka T, Sugimoto Y, Kato H
Development of acquired resistance to gefitinib after an initial good response is common. Recently, it was reported that this acquired resistance is related to a secondary mutation associated with a substitution of threonine by methionine at codon 790 (T790M) of the epidermal growth factor receptor (EGFR) gene. In this report, we present a “never smoking” woman with advanced lung cancer who showed acquired resistance to gefitinib, and analysis of autopsy samples revealed no evidence of EGFR mutations in either exons 18-21 or codon 790, and positive immunostaining for breast cancer resistance protein (BCRP). We describe, for the first time, a case in which expression of BCRP was associated with acquired resistance to gefitinib, independent of EGFR mutations.
PMID: 17618705 [PubMed - indexed for MEDLINE]
cancervisa